A research team at the RIKEN Center for Emergent Matter Science (CEMS) in Japan has developed a diagnostic system that can rapidly and sensitively measure the amount of antibodies in the blood that can protect us from SARS-CoV-2, the virus that causes COVID-19.
St. Jude Children’s Research Hospital scientists detail how inflammasomes act as integral components of mega-cell death complexes called PANoptosomes for host defense in live viral and bacterial infections.
Lab studies reveal protein HSP27’s role in blood vessel leakage, opening the possibility that therapeutically dialing its activity up or down might stabilize patients with sepsis.
A buildup of coronavirus in the lungs is likely behind the steep mortality rates seen in the pandemic, a new study finds. The results contrast with previous suspicions that simultaneous infections, such as bacterial pneumonia or overreaction of the body’s immune defense system, played major roles in heightened risk of death, the investigators say.
Nearly 90% of people taking immunosuppressants to treat autoimmune conditions produce an antibody response to COVID-19 vaccination, but the response is weaker than those generated by healthy people, according to a study by researchers at Washington University School of Medicine in St. Louis.
A new study shows that two months after the second Pfizer/Moderna vaccination, antibody response decreases 20% in adults with prior cases of COVID-19. The study also tests how well current vaccines resist emerging variants.
The breast milk of lactating mothers vaccinated against COVID-19 contains a significant supply of antibodies that may help protect nursing infants from the illness, according to new research from the University of Florida.
August 16, 2021 – Chulalongkorn Memorial Hospital, Thai Red Cross Society, and the Vaccine Research Center, Faculty of Medicine, Chulalongkorn University (CVRC) held a press conference on the progress of clinical trials for the Thai “ChulaCov19” mRNA vaccine. The clinical trial (Phase 1) was administered in healthy volunteers who are found to have good immunity after they have been vaccinated. The volunteers’ antibodies have been greatly boosted to prevent the original strain of the virus, and four other variants, namely Alpha, Beta, Gamma, and Delta. Manufacturing and preparation for registration to be used in an emergency are underway.
For those with backyard poultry, like chickens or ducks, a Texas A&M AgriLife expert encourages taking precautions against salmonella exposure as cases spike across the U.S.
A recent study led by an Iowa State University entomologist explores the different kinds of cells that make up mosquito immune systems. The research could shed light on how mosquitoes transmit malaria.
Cedars-Sinai Cancer researchers have discovered that intestinal microorganisms help regulate anti-tumor immune responses to radiation treatments, and that fungi and bacteria have opposing effects on those responses.
Researchers at Washington University School of Medicine in St. Louis have identified an antibody that is highly protective against a broad range of viral variants.
A monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca reduced the risk of symptoms in a study of immunocompromised and chronically ill adults later exposed to the virus by 77%, the company announced today.
In a new article published in JNCI Cancer Spectrum, Moffitt Cancer Center researchers describe a prediction model they have created that includes information calculated from computed tomography images that can identify non-small cell lung cancer patients who are not likely to respond to immunotherapy.
The early COVID-19 vaccination campaign in the U.S. prevented nearly 140,000 deaths and 3 million cases of COVID-19 by the second week of May, according to a new study.
Expert Q&A: Do breakthrough cases mean we will soon need COVID boosters? The extremely contagious Delta variant continues to spread, prompting mask mandates, proof of vaccination, and other measures. Media invited to ask the experts about these and related topics.
A new preclinical study led by researchers at the UCLA Jonsson Comprehensive Cancer Center suggests that treating people who have aggressive cancers, including melanoma, pancreatic and colorectal cancers, with immune checkpoint inhibitors, quickly followed with mutation-targeted therapy, can help overcome treatment resistance and help people live longer.